# A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza

> **NCT07159763** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 7500 (estimated)

## Conditions studied

- Influenza

## Interventions

- **COMBINATION_PRODUCT:** CD388 Injection
- **COMBINATION_PRODUCT:** Placebo

## Key facts

- **NCT ID:** NCT07159763
- **Lead sponsor:** Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-09-25
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 7500 (ESTIMATED)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07159763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07159763, "A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07159763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*